Literature DB >> 2623137

Treatment of chronic hepatitis delta virus (HDV) infection with human lymphoblastoid alpha interferon.

P Farci1, P Karayiannis, M G Brook, A Smedile, M E Lai, A Balestrieri, J A Saldanha, J Monjardino, J Gerin, H C Thomas.   

Abstract

Ten patients with evidence of continuing HDV replication were treated with lymphoblastoid alpha-interferon and eight more were followed as a non-randomized control group. Four out of eight patients who completed one year of follow-up had cleared HDV-RNA from the serum whilst none of the control group did so. In these four responding cases there was a transient increase in transaminase levels during treatment and in two, this was followed by improvement. One patient also cleared HBV and seroconverted to anti-HBs (antibody to hepatitis B surface antigen--HBsAg). In one patient with sustained loss of HDV, recurrence of HDV infection was detected 18 months after completion of treatment. These data suggest that alpha-interferon can inhibit HDV replication in the short term but relapse after one to two years may occur. Inhibition of HDV-RNA is associated with improvement in the inflammatory liver disease and now larger studies are required to determine whether it influences survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2623137

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  3 in total

Review 1.  Interferon alpha for chronic hepatitis D.

Authors:  Zaigham Abbas; Muhammad Arsalan Khan; Mohammad Salih; Wasim Jafri
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

3.  Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis.

Authors:  Seyed-Moayed Alavian; Seyed Vahid Tabatabaei; Bita Behnava; Mario Rizzetto
Journal:  J Res Med Sci       Date:  2012-10       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.